FORWARD II Phase 1b trial

May 25, 2018May 25, 2018

Mirvetuximab Soravtansine Combo Therapies Show Promise for Ovarian Cancer, Clinical Trial Shows

News

Combinations of mirvetuximab soravtansine (IMGN853) with either Avastin (bevacizumab) or Paraplatin (carboplatin) are showing promise in certain ovarian cancer patients, particularly those who received multiple prior lines of therapy, the investigational therapy’s developer, ImmunoGen, recently announced. ... Read more

May 7, 2018

Phase 3 Trial of Mirvetuximab Soravtansine in Ovarian Cancer OK’d to Continue as Planned

News

A Phase 3 trial evaluating ImmunoGen’s mirvetuximab soravtansine (IMGN853) in platinum-resistant ovarian cancer patients is on its way to achieving its objectives, an interim futility analysis shows. As a result, the FORWARD ... Read more

May 22, 2017

ImmunoGen’s Investigative Therapy for Ovarian Cancer Shows Potential in Clinical Studies

News

ImmunoGen will show promising safety and efficacy data of its investigative treatment mirvetuximab soravtansine for the treatment of FRα-positive epithelial ovarian cancer (EOC). The positive top-line data will be presented in three poster ... Read more